BLU 222
Alternative Names: BLU-222Latest Information Update: 28 May 2025
At a glance
- Originator Blueprint Medicines
- Class 1 ring heterocyclic compounds; 2 ring heterocyclic compounds; Amines; Antineoplastics; Ethers; Fluorocarbons; Pyrazines; Pyrazoles; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase I/II HER2 negative breast cancer; Solid tumours
- Preclinical Gynaecological cancer; Ovarian cancer
- No development reported Cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Cancer in USA
- 25 Apr 2025 Pharmacodynamics and adverse evenst data from a preclinical trial in Small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 02 Jul 2024 Chemical structure information added